CMIC HOLDINGS Co., Ltd. has established CMIC BIO Co., Ltd., a fully-owned subsidiary that offers Contract Development and Manufacturing Organization (hereinafter CDMO) services for biopharmaceutical drug substance. CMIC Bio has a single-use facility in Shizuoka, Japan for process development and GMP manufacturing of antibody drug using mammalian cell line. The facility will be fully operational beginning October 2020.

For the period from April 2014 to September 2019, CMIC JSR Biologics Co., Ltd. participated in the Japan Science and Technology Agency’s Program (NexTEP) (Project name: design and  manufacturing technology of multispecific antibodies). “Research has been conducted in the fields of manufacturing and quality control of biotechnology-derived pharmaceuticals, with a focus on the manufacturing process development of bispecific antibodies. Based on these experiences, we established CMIC Bio and the biopharmaceutical drug substances CDMO business.” At CMIC Bio, we have personnel with abundant experience at pharmaceutical companies and have strengths in GMP API manufacturing bases in Japan to assist in accelerating the development speed of biopharmaceuticals,” said Hiroshi Kosaku, President of CMIC Pharmaceutical Sciences.

CMIC Group provides services from non-clinical testing, clinical trials, GMP manufacturing of biopharmaceuticals to commercialization and post market.